Opportunities and challenges of mRNA technologies in development of dengue virus vaccine

Opportunities and challenges of mRNA technologies in development of dengue virus vaccine

Blog Article

Dengue virus (DENV) is a mosquito-borne virus with a significant human health concern.With 390 million infections annually and 96 million showing clinical lock shock and barrel art symptoms, severe dengue can lead to life-threatening conditions like dengue hemorrhagic fever (DHF) and dengue shock syndrome (DSS).The only FDA-approved vaccine, Dengvaxia, has limitations due to antibody-dependent enhancement (ADE), necessitating careful administration.

The recent pre-approval of TAK-003 by WHO in 2024 highlights ongoing efforts incredibleindiatourtravels.com to improve vaccine options.This review explores recent advancements in dengue vaccine development, emphasizing potential utility of mRNA-based vaccines.By examining current clinical trial data and innovations, we aim to identify promising strategies to address the limitations of existing vaccines and enhance global dengue prevention efforts.